MDXHEALTH SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.88 USD | +0.70% |
|
+3.97% | -26.90% |
| May. 01 | MDxHealth SA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 01 | Transcript : MDxHealth SA, Q1 2024 Earnings Call, May 01, 2024 |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 78.66M 85.49M | Sales 2025 * | 89.78M 97.57M | Capitalization | 72.29M 78.56M |
|---|---|---|---|---|---|
| Net income 2024 * | -26M -28.26M | Net income 2025 * | -17M -18.47M | EV / Sales 2024 * | 2.23 x |
| Net Debt 2024 * | 103M 112M | Net Debt 2025 * | 121M 131M | EV / Sales 2025 * | 2.15 x |
| P/E ratio 2024 * |
-2.86
x | P/E ratio 2025 * |
-4.24
x | Employees | 300 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on MDxHealth SA
| 1 day | +0.70% | ||
| 1 week | +3.97% | ||
| Current month | +15.20% | ||
| 1 month | +25.22% | ||
| 3 months | -19.55% | ||
| 6 months | +15.20% | ||
| Current year | -26.90% |
1 week
2.60
2.95
1 month
2.213.20
Current year
2.214.64
1 year
2.214.64
3 years
0.0017.80
5 years
0.0017.80
10 years
0.0061.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 62 | 19-02-17 | |
Ron Kalfus
DFI | Director of Finance/CFO | 50 | 19-07-21 |
Miriam Reyes
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Donnie Hardison
BRD | Director/Board Member | 74 | 21-09-28 |
Eric Bednarski
BRD | Director/Board Member | 53 | 20-07-29 |
Hilde Windels
BRD | Director/Board Member | 59 | 17-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 2.88 | +0.70% | 35,984 |
| 24-05-16 | 2.86 | +1.60% | 28,735 |
| 24-05-15 | 2.815 | -2.26% | 42,104 |
| 24-05-14 | 2.88 | -0.69% | 42,879 |
| 24-05-13 | 2.9 | +4.69% | 26,097 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
MDxHealth SA is a Belgium-based healthcare company which provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Companyâs tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The Company's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.
Calendar
2024-05-29
- Annual General Meeting
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.88
USD
Average target price
7.25
USD
Spread / Average Target
+151.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.90% | 78.59M | |
| -0.09% | 42.12B | |
| +49.62% | 42.05B | |
| -4.96% | 29.18B | |
| +11.18% | 26.02B | |
| -21.95% | 18.9B | |
| +8.61% | 13.21B | |
| +24.73% | 12.17B | |
| +28.31% | 12.16B | |
| -6.26% | 11.42B |
- Stock Market
- Equities
- MDXH Stock